u/careful_gradient32

Kept a log specifically because there is so little published. It is one person and it is not data.

quantity limits are as common a barrier as coverage itself

formulary decisions are provincial, so the province is the first fact

Adding the fastest step — ask the pharmacist. They can usually check in minutes.

the glucagon component is why the metabolic story reads differently

Went up slowly, deliberately, because everything on this board says the escalation is where trouble lives. Uneventful so far and I am not going to pretend that is a finding.

What the glucagon arm is doing, as best anyone can say from public data.

GLP-1 and GIP agonism cover appetite and insulin secretion in ways that are now reasonably well characterised. Glucagon receptor agonism is the third leg and it is associated with increased energy expenditure and with effects on hepatic fat.

Mechanistically that is why this compound reads as a different proposition rather than a stronger version of a dual agonist. Clinically, the size and durability of that difference in humans is precisely what is not yet established, and anyone telling you otherwise is filling a gap with confidence.

heart rate is the thing people report watching

Sent a vial to Medutest out of curiosity. Result was 97.4% against a claimed 97.0%, which is the first independent number I had seen for this compound anywhere.

Confused a rejected claim with a denied authorization for a month and pursued entirely the wrong process.

the TRIUMPH programme is still running, so anything definitive is premature

Agreed. Province first — coverage is a provincial decision and national answers are wrong somewhere by construction.

A rejected claim at the pharmacy counter and a denied authorization are different events with different remedies. The first can be an administrative or quantity issue; the second is a determination you can appeal.

dose escalation in the trials was slow for a reason

This is the sentence the rest of the board should read first. Phase 2 is not a label.

What the glucagon arm is doing, as best anyone can say from public data.

GLP-1 and GIP agonism cover appetite and insulin secretion in ways that are now reasonably well characterised. Glucagon receptor agonism is the third leg and it is associated with increased energy expenditure and with effects on hepatic fat.

Mechanistically that is why this compound reads as a different proposition rather than a stronger version of a dual agonist. Clinically, the size and durability of that difference in humans is precisely what is not yet established, and anyone telling you otherwise is filling a gap with confidence.

Correction: TRIUMPH is the phase 3 programme. The number you are quoting is from the phase 2 readout, which is a different trial.

Agreed, and the framing that helps is: this is a phase 2 compound with phase 3 running.

Agreed, and the glucagon arm is exactly why the comparison threads do not work.

Correcting my own comment above: that figure was the 36-week interim, not the 48-week endpoint.

Formulary criteria are revised, and plan renewal is a natural point at which a previously refused request may succeed without anything about the applicant changing.

Cosigning the escalation point. Almost every difficult report on this board is from somebody who went up quickly.

Careful with the rankings. A phase 2 result and a phase 3 result are not on the same evidential footing and cannot be listed in one table.

Correcting my own comment above: that figure was the 36-week interim, not the 48-week endpoint.

Agreed, and the glucagon arm is exactly why the comparison threads do not work.

Provincial plan, employer plan, or paying cash?

Cash pricing, which people skip because they assume coverage is the only route.

incretin_ivy is right that a rejected claim and a denied authorization are different animals.

Spent three weeks on what turned out to be a quantity limit rather than a coverage question.

Phase 2 estimates effect and finds a dose range. Phase 3 estimates it precisely in a bigger population and catches what phase 2 was too small to see. Treating them as the same tier of evidence is the recurring error here.

Push back: approval by the national regulator says nothing about whether any plan will pay.

Glucagon receptor agonism is associated with increased energy expenditure and with hepatic effects. That is a mechanistic story with strong preclinical support and limited phase 2 human data.

phase 2 data only, and people quote it like it is a label

The standing caveat, written out properly because it keeps getting compressed into a footnote.

This is the sentence the rest of the board should read first. Phase 2 is not a label.

The standing caveat, written out properly because it keeps getting compressed into a footnote.

Nothing containing this compound is approved by any regulator. Research-use-only material is not approved for human use. That is not a legal formality on this board — it is why there is so little independent data, why the escalation schedules people post are invented, and why nobody here can answer a dosing question.

What this board can usefully do is read the published trials carefully, log independent purity results, and be honest about how thin the evidence base is. Everything else belongs somewhere with a clinician in it.

Confused a rejected claim with a denied authorization for a month and pursued entirely the wrong process.

a lot of the confident posting here is extrapolation

Kept a log specifically because there is so little published. It is one person and it is not data.

The phase 2 readout ran to 48 weeks in a few hundred participants with a slow escalation. Both the size and the duration matter when people quote the headline number.

Cosigning the escalation point.

Agreed, and the glucagon arm is exactly why the comparison threads do not work.

Has anyone posted an independent test on this compound recently?

Disagree with this specific inference. A 48-week readout does not tell you the shape of the curve after it.